Ultime notizie per Hyliion Holdings (AMEX:HYLN) Azioni

Hyliion Holdings

Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it is also focused on mobile applications, including vehicles and marine technologies. The Company aims to offer innovative, yet practical solutions that contribute positively to the environment in the energy economy.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

Envoy Medical, Inc. - Class A Common Stock

COCH

HYLN

SXTP

Scopri le penny stock sotto i $5 in cui Hyliion e altri due titoli stanno attirando l&#39;attenzione degli insider.

Penny stock sotto i $5: Hyliion e altri 2 titoli sotto osservazione

Hyliion Holdings Corp. Class A Common Stock

Hyliion Holdings Corp

In the current session, the stock is trading at $49.52, after a 1.56% increase. Over the past month, Cheesecake Factory Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) stock increased by 6.47%, and in the past year, by 53.42%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1737479710_0.png" alt="Past Year Chart" />

<h3>Evaluating Cheesecake Factory P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Cheesecake Factory has a lower P/E than the aggregate P/E of 80.99 of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1737479710_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

CAKE

A Look Into Cheesecake Factory Inc's Price Over Earnings

RBC Capital analyst Scott Heleniak reiterates Principal Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Sector Perform and maintains $91 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Sector Perform on Principal Finl Gr, Maintains $91 Price Target

Raymond James analyst Josh Beck upgrades Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) from Outperform to Strong Buy and raises the price target from $225 to $300.

Upgrades

Raymond James Upgrades Wix.com to Strong Buy, Raises Price Target to $300

WIIM

LUNR

Intuitive Machines shares are trading higher. The stock may be up on President Trump's comments on space travel and Mars at his inauguration.

Raymond James analyst Josh Beck maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Strong Buy and raises the price target from $150 to $200.

RDDT

Raymond James Maintains Strong Buy on Reddit, Raises Price Target to $200

RBC Capital analyst Luca Issi reiterates Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Outperform and maintains $24 price target.

LXEO

RBC Capital Reiterates Outperform on Lexeo Therapeutics, Maintains $24 Price Target

Bridgewater Associates founder Ray Dalio believes the key to lowering interest rates and balancing out the bond market is reducing the <a href="https://www.benzinga.com/government/regulations/25/01/43059174/buy-long-duration-bonds-says-bank-of-america-strategist">U.S. budget deficit</a>.
What To Know: In an interview from the&nbsp;World Economic Forum on <a href="https://www.cnbc.com/2025/01/21/dalio-says-cutting-budget-deficit-is-crucial-to-stabilize-bond-market.html">CNBC&#8217;s</a> &#8220;Squawk Box&#8221; Tuesday morning, Dalio indicated that there&#8217;s a supply-demand imbalance in the bond market that can be improved if the projected deficit could be lowered to 3%.
&#8220;We have a projected deficit of 7.5% of GDP. That means all those bonds have to be sold,&#8221; Dalio said.
See Also: <a href="https://www.benzinga.com/25/01/43103527/mexican-peso-canadian-dollar-slide-as-trump-threatens-25-tariffs-expert-eyes-price-hikes-on-typical-us-breakfast">Mexican Peso, Canadian Dollar Slide As Trump Threatens 25% Tariffs, Economist Eyes Price Hikes On &#8216;Typical US Breakfast&#8217;</a>
&#8220;When I calculate who are the buyers of the bonds, there will not be enough buyers. And then where it could be worse in this dynamic is those who own bonds also sell the bonds, and when that happens there&#8217;s a tremendous supply &#8230; and then we have problems. We can get into what it looks like, but it&#8217;s happened many times before. So we have to stabilize that, and we can do it.&#8221;
The billionaire investor&nbsp;told CNBC that he calls it &#8220;the 3% solution.&#8221; Most people understand that you can lower the deficit by <a href="https://www.benzinga.com/personal-finance/24/10/41564246/from-10-trillion-to-35-trillion-how-government-spending-has-spiraled-out-of-control">cutting spending</a> and raising taxes, but they often overlook what happens when the economy is strong.
&#8220;If you do it when the economy is good, you will get a lower interest rate. A lower interest rate means less cost of the debt because we have so much debt that the interest costs on the debt is more important than spending and taxes,&#8221; Dalio said.
The federal budget jumped close to 40% in 2024 versus the prior year, pushing the national debt above $36 trillion. Dalio told CNBC that it&#8217;s up to the politicians to work together to figure it out. It&#8217;s certainly achievable if everyone agrees on the 3% target, he added.
&#8220;Our problem isn't the deficit. Our problem is the politics,&#8221; Dalio said. &#8220;The fragmented politics.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43101541/exclusive-powell-co-will-wait-wisdomtree-expert-says-on-why-investors-need-smarter-bond-strategy">EXCLUSIVE: &#8216;Powell &amp; Co. Will Wait&#8217; — WisdomTree Expert On Why Investors Need Smarter Bond Strategy</a></li>
</ul>
Image via Shutterstock

Government

Politics

Billionaire Ray Dalio Says US Budget Deficit Isn't The Problem, It's 'Fragmented' Politics

Raymond James analyst Josh Beck maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Strong Buy and raises the price target from $675 to $725.

Raymond James Maintains Strong Buy on Meta Platforms, Raises Price Target to $725

Raymond James analyst Josh Beck upgrades MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) from Outperform to Strong Buy and maintains the price target from $2250 to $2250.

MELI

Raymond James Upgrades MercadoLibre to Strong Buy, Maintains Price Target to $2250

RBC Capital analyst Karl Shepard reiterates Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Outperform and maintains $20 price target.

HBAN

RBC Capital Reiterates Outperform on Huntington Bancshares, Maintains $20 Price Target

Raymond James analyst Josh Beck maintains GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Strong Buy and raises the price target from $185 to $230.

GDDY

Raymond James Maintains Strong Buy on GoDaddy, Raises Price Target to $230

RBC Capital analyst Luca Issi reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Outperform and maintains $67 price target.

RBC Capital Reiterates Outperform on Avidity Biosciences, Maintains $67 Price Target

Tuesday, Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.
On Friday, Moderna announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/ac43067713/moderna-announces-updates-on-pandemic-influenza-program" rel="noreferrer noopener">pandemic influenza vaccines</a>.
The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a>
The project will support the late-stage development and licensure of pre-pandemic mRNA-based vaccines. The agreement will also expand clinical studies for up to five additional subtypes of pandemic influenza.
In 2023, Moderna commenced a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA-1018) in healthy adults 18 years and older.
The study included vaccine candidates against H5 and H7 avian influenza viruses. Based on the preliminary data from the Phase 1/2 study, Moderna is preparing to advance mRNA-1018 into Phase 3.
The company looks forward to sharing the Phase 1/2 results at an upcoming scientific meeting.
This $590 million award has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
Earlier this month, Moderna announced business updates and progress&nbsp;across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, <a target="_blank" href="https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives" rel="noreferrer noopener">and latent and other viruses.</a>
Price Action: MRNA stock is up 5.75% at $36.02 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43102213/whats-going-on-with-the-stock-of-foresight-autonomous-today" target="_blank" rel="noreferrer noopener">Foresight Autonomous Inks Commercial Cooperation Pact With Autonomous Drone Manufacturer: Details</a></li>
</ul>
Photo by Lutsenko_Oleksandr on Shutterstock.

Biotech

Equities

Large Cap

Health Care

Contracts

Movers

General

MRNA

Why Is Moderna Stock Trading Higher On Tuesday?

Speaking at the World Economic Forum in Davos 2025, Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong placed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) on a higher pedestal than gold as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42114875/coinbase-ceo-brian-armstrong-stands-out-as-candidate-for-donald-trumps-reported-crypto-czar-position-cardano-co-founder-says">store of value for governments</a>.
What Happened: In an <a href="https://www.youtube.com/watch?v=dl9ruFvPlsw">interview</a> with CNBC, Armstrong reflected on spending two days in Washington during Donald Trump's inauguration, describing the event as the "dawn of a new day for crypto." 
He expressed optimism about the new administration&#8217;s potential to establish clear regulations and pass <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43076398/trumps-expected-executive-orders-bitcoins-bullish-surge-and-more-this-week-in-crypto">crypto-friendly legislation</a>, setting the stage for significant investment and innovation. 
He added that crypto is still in "infancy" and it is a very exciting phase.
Armstrong also underscored crypto's early-stage growth, highlighting factors like the rise of Bitcoin ETFs, increased stablecoin payments, and the growing interest of Fortune 500 companies in piloting crypto initiatives. 
He emphasized that Bitcoin, as a global digital asset, could make financial systems faster, cheaper and more efficient, ultimately promoting financial freedom worldwide.
In December 2024, Armstrong openly <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42291096/coinbase-ceo-brian-armstrong-the-us-government-should-never-sell-bitcoin">opposed the U.S. government's decision to sell its Bitcoin</a> holdings, arguing that such assets should be retained as part of a long-term strategy.
Armstrong also hinted at potential partnerships, including integrating <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42741117/coinbase-ceo-brian-armstrong-a-stablecoin-integration-x-would-great-feature">USDC transfers into Elon Musk&#8217;s X platform</a>, signaling a pro-crypto alignment with global financial systems.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43085738/trumps-crypto-silence-inauguration-omission-sparks-questions-after-history-of-mixed-signals">Trump&#8217;s Crypto Silence: Inauguration Omission Sparks Questions After History Of Mixed Signals</a>
What's Next: Armstrong anticipates that the administration&#8217;s first steps will include executive orders directing U.S. government agencies to collaborate on clear crypto regulations. 
Key initiatives could include Attracting capital and enabling startups to thrive in the U.S. and protecting the right to own Bitcoin and use custodial wallets without fear of persecution or de-banking.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43088563/bitcoin-vs-gold-peter-schiff-decodes-trumps-golden-age-reference-in-inaugural-speech">Peter Schiff On Trump&#8217;s Crypto Snub In Inaugural Speech: &#8216;He Invoked Gold, Not Bitcoin&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

Coinbase CEO Brian Armstrong Says Bitcoin's Future Is Bright: 'The Dawn Of A New Day For Crypto'

Raymond James analyst Josh Beck maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Strong Buy and raises the price target from $230 to $260.

AMZN

Raymond James Maintains Strong Buy on Amazon.com, Raises Price Target to $260

RBC Capital analyst Luca Issi reiterates Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and maintains $26 price target.

APLS

RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $26 Price Target

Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) and Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) are trending across social media platforms on Tuesday. Both oil companies are set to release earnings soon, with Shell expected to report its 2024 fiscal-year fourth-quarter earnings on Jan. 30 and Chevron on Jan. 31.
Analysts expect Shell to report earnings per share of $1.56 and revenue of $49.23 billion. 
Previously, the company <a href="https://www.benzinga.com//node/42870812">lowered its guidance</a> for integrated gas production for the fourth-quarter, now expecting between 880 – 920 kboe/d oil-equivalent barrels per day. This is down from its previous forecast of 900 – 960 boe/d.
Shell also lowered its forecast for LNG production to between 6.8 million and 7.2 million metric tons, down from the previous range of 6.9 million to 7.5 million metric tons.
Analysts estimate earnings per share of $2.19 and revenue of $46.93 billion for Chevron&#8217;s fourth quarter. Chevron had previously indicated that it expects to close asset deals in Canada, Congo, and Alaska throughout the quarter. Additionally, the company said it is working on cost reduction initiatives and aims to achieve $2-3 billion in structural cost savings by the end of 2026, starting from 2024.
Ahead of earnings, Raymond James analyst Justin Jenkins maintained an outperform rating on Chevron and raised the price target from&nbsp;$175&nbsp;to&nbsp;$180.
See Also: <a href="https://www.benzinga.com/news/25/01/43101920/whats-going-on-with-ge-vernova-gev-stock-ahead-of-q4-earnings">What&#8217;s Going On With GE Vernova (GEV) Stock Ahead Of Q4 Earnings?</a>
Price Action: At the time of publication, Chevron stock is trading 0.75% lower at $160.26 and Shell shares are trading 0.26% lower at $66.90, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

SHEL

What's Going On With Shell And Chevron Stock Tuesday?

Truist Securities analyst David Smith maintains State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Hold and lowers the price target from $106 to $104.

Truist Securities Maintains Hold on State Street, Lowers Price Target to $104

Truist Securities analyst Brandon King maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Hold and raises the price target from $25 to $26.

Truist Securities Maintains Hold on Regions Finl, Raises Price Target to $26

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

ALNY

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

Hyliion Holdings soars to a new high after insider buying action

Hyliion Holdings: AI Data Center Opportunity In Focus - Hold

Undercovered Dozen: Arqit Quantum, CleanSpark, Sezzle, STAG Industrial +

EV Company News For The Month Of November 2024

Hyliion gets $6M federal grant

Hyliion Holdings (HYLN) announced it has been awarded a $6M grant from the U.S. Department of Energy's DOE Methane Emissions Reduction Program. For...

DOE awards Hyliion $6M grant to advance methane emission reductions

Hyliion: New Product, Same Problems

EV Company News For The Month Of December 2024

Hyliion purchases M line additive manufacturing systems from Colibrium Additive

Hyliion Holdings (HYLN) has taken delivery of their first M Line additive manufacturing system from Colibrium Additive, a GE Aerospace (GE) company...

Hyliion Holdings buys M Line additive manufacturing systems from Colibrium

ARQQ

ARQQW

AYRO

BAMXF

BATT

BCCMY

BLBD

BLNK

BMCLF

BYDDF

BYDDY

BYMOF

CLSK

CXDO

DNFGF

DNFGY

EQGPF

EVGO

EVGOW

EVTV

FUJHF

FUJHY

GDHLF

GELYF

GELYY

GOEV

GOEVW

GWLLF

GWLLY

HNDAF

HYMTF

KNDI

LAAOF

LCID

MAHMF

MBGAF

MBGYY

MMTOF

MZDAF

MZDAY

NIOIF

NSANF

NSANY

POAHF

POAHY

PSNY

PSNYW

RACE

RIVN

RNLSY

RNSDF

SEZL

SEZNL

STAG

STLA

SZKMF

SZKMY

TOYOF

TSLA

VFSWW

VLKAF

VLKPF

VNET

VRTX

VWAGY

VWAPY

WKHS

WTRG

XIACF

XIACY

XPEV

XPNGF

Press Releases

Hyliion Awarded US Government Contract for Game-Changing KARNO Generator for the US Navy

Hyliion's KARNO Linear Generator Now Qualifies Under California's Renewables Portfolio Standard (RPS)

Hyliion Signs Letter of Intent with ANA to Deploy KARNO Generators in the Mobile Power Generation Market

Hyliion Holdings Corp. Announces Transfer of Stock Listing to NYSE American

Hyliion Holdings Schedules Third Quarter Financial Results Conference Call and Webcast for November 15, 2024

Hyliion to Present at Sidoti Virtual Conference

Hyliion Successfully Showcases the KARNO Generator's Uninterrupted Multi-Fuel Operation

Hyliion Holdings Reports Third-Quarter 2024 Financial Results

Hyliion Awarded $6 Million Federal Grant to Advance Methane Emission Reductions in the Oil and Gas Industry

Hyliion Purchases M Line Additive Manufacturing Systems from Colibrium Additive to Scale Production of KARNO Generators

Comments

Hyliion Holdings

Notizie

Ultime notizie per Hyliion Holdings (AMEX:HYLN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO